← Oncology Approval Tracker

FDA DECISION ·

Pemazyre

pemigatinib · Incyte

FDA approvalNew or expanded indicationMyeloid/lymphoid neoplasms
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory myeloid or lymphoid neoplasms with an FGFR1 rearrangement.

LAMPGEN ANALYSIS

Why it matters

The action extends an FGFR inhibitor from a solid tumor setting to a rare hematologic neoplasm defined by FGFR1.

What research teams should watch

Confirm the rearrangement and involved lineage and coordinate testing and longitudinal monitoring with hematopathology.

PRIMARY RECORDS

Sources